Amphiphilic curcumin conjugate-forming nanoparticles as anticancer prodrug and drug carriers: In vitro and in vivo effects

Nanomedicine

Volumn 5, Issue 6, 2010, Pages 855-865

  Tang, Huadong ^b   Murphy, Caitlin J ^c   Zhang, Bo ^b   Shen, Youqing ^a,b   Sui, Meihua ^a   Van Kirk, Edward Alva ^c   Feng, Xiaowen ^d   Murdoch, William J ^c  

^a ZHEJIANG UNIVERSITY   (China)

^b UNIVERSITY OF WYOMING   (United States)

^c UNIVERSITY OF WYOMING   (United States)

^d ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

anticancer; curcumin; drug carrier; nanoparticle

Indexed keywords

AMPHOPHILE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CURCUMIN; CURCUMIN OLIGO(ETHYLENE GLYCOL); DOXORUBICIN; DRUG CARRIER; ESTERASE; GLUTATHIONE; NANOPARTICLE; PRODRUG; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE ARREST; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CURCUMIN; DRUG CARRIERS; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MICE; MICE, NUDE; NANOPARTICLES; PRODRUGS;

EID: 77956079868     PISSN: 17435889     EISSN: None     Source Type: Journal    
DOI: 10.2217/nnm.10.67     Document Type: Article

References (50)

1. Jagtap S, Meganathan K, Wagh V, Winkler J, Hescheler J, Sachinidis A: Chemoprotective mechanism of the natural compounds, epigallocatechin-3-O- gallate, quercetin and curcumin against cancer and cardiovascular diseases. Curr. Med. Chem. 16, 1451-1462 (2009).
2. Aggarwal BB, Surh YH, Shishodia S: The Molecular Targets and Therapeutic Uses of Curcumin in Health and Disease. Springer, NY, USA (2007).
3. Strimpakos AS, Sharma RA: Curcumin: preventive and therapeutic properties in laboratory studies and clinical trials. Antioxid. Redox Signaling 10, 511-546 (2008).
4. Lin YG, Kunnumakkara AB, Nair A et al.: Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kB pathway. Clin. Cancer Res. 13, 3423-3430 (2007).
5. Kunnumakkara AB, Anand P, Aggarwal BB: Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett. 269 199-225 (2008).
6. Karunagaran D, Rashmi R, Kumar TR: Induction of apoptosis by curcumin and its implications for cancer therapy. Curr. Cancer Drug Target 5, 117-129 (2005).
7. Rajesh LT, Anuj S, Radha KM: Multiple molecular targets in cancer chemoprevention by curcumin. AAPS J. 8, E443-E449 (2006).
8. Shukla S, Zaher H, Hartz A, Bauer B, Ware JA, Ambudkar SV: Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice. Pharm. Res. 26, 480-487 (2009).
9. Zhang W, Tan TMC, Lim L-Y: Impact of curcumin-induced changes in P-glycoprotein and CYP3A expression on the pharmacokinetics of peroral celiprolol and midazolam in rats. DrugMetab. Dispos. 35, 110-115 (2006).
10. Li L, Ahmed B, Mehta K, Kurzrock R: Liposomal curcumin with and without oxaliplat, effects on cell growth, apoptosis, and angiogenesis in colorectal cancer. Mol. Cancer Ther. 6, 1276-1282 (2007).
11. Dorai T, Cao YC, Dorai B, Buttyan R, Katz AE: Therapeutic potential of curcumin in human prostate cancer. III. Curcumin inhibits proliferation, induces apoptosis, and inhibits angiogenesis of LNCaP prostate cancer cells in vivo. Prostate 47 293-303 (2001).
12. Somers-Edgar TJ, Scandlyn MJ, Stuart EC, Le Nedelec MJ, Valentine SP, Rosengren RJ: The combination of epigallocatechin gallate and curcumin suppresses ERa -breast cancer cell growth in vitro and in vivo. Int. J. Cancer 122, 1966-1971 (2008).
13. Narayanan Narayanan K, Nargi D, Randolph C, Narayanan Bhagavathi A: Liposome encapsulation of curcumin and resveratrol in combination reduces prostate cancer incidence in PTEN knockout mice. Int. J. Cancer 125, 1-8 (2009).
14. Milacic V, Banerjee S, Landis-Piwowar KR, Sarkar FH, Majumdar APN, Dou QP: Curcumin Inhibits the proteasome activity in human colon cancer cells in vitro and in vivo. Cancer Res. 68, 7283-7292 (2008).
15. Dujic J, Kippenberger S, Ramirez-Bosca A et al.: Curcumin in combination with visible light inhibits tumor growth in a xenograft tumor model. Int. J. Cancer 124, 1422-1428 (2009).
16. William BM, Goodrich A, Peng C, Li S: Curcumin inhibits proliferation and induces apoptosis of leukemic cells expressing wild-type or T315I-BCR-ABL and prolongs survival of mice with acute lymphoblastic leukemia. Hematology 13, 333-343 (2008).
17. Purkayastha S, Berlinerb A, Fernandoa SS et al.: Curcumin blocks brain tumor formation. Brain Res. 1266, 130-138 (2009).
18. Shankar S, Ganapathy S, Chen Q, Srivastava RK: Curcumin sensitizes TRAIL-resistant xenografts: molecular mechanisms of apoptosis, metastasis and angiogenesis. Mol. Cancer 7, 16 (2008).
19. Ajaikumar BK, Preetha A, Bharat BA: Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett. 269 199-225 (2008).
20. Chen H-W, Lee J-Y, Huang J-Y et al.: Curcumin inhibits lung cancer cell invasion and metastasis through the tumor suppressor HLJ1. Cancer Res. 68, 7428-7438 (2008).
21. Narasimhan M, Ammanamanchi S: Curcumin blocks RON tyrosine kinase-mediated invasion of breast carcinoma cells. Cancer Res. 68, 5185-5192 (2008).
22. Kunnumakkara AB, Diagaradjane P, Guha S etal.: Curcumin sensitizes human colorectal cancer xenografts in nude mice to g-radiation by targeting nuclear factor-kB-regulated gene products. Clin. Cancer Res. 14, 2128-2136 (2008).
23. Javvadi P, Segan a T, Tuttle SW, Koumenis C: The chemopreventive agent curcumin is a potent radiosensitizer of human cervical tumor cells via increased reactive oxygen species production and overactivation of the mitogen-activated protein kinase pathway. Mol. Pharmacol. 73, 1491-1501 (2008).
24. Kunnumakkara a B, Guha S, Krishnan S, Diagaradjane P, Gelovani J, Aggarwal BB: Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kB-regulated gene products. Cancer Res. 67, 3853-3861 (2007).
25. Kamat AM, Sethi G, Aggarwal BB: Curcumin potentiates the apoptotic effects of chemotherapeutic agents and cytokines through downregulation of nuclear factor-kB and nuclear factor-kB-regulated gene products in IFN-a -sensitive and IFN-a -resistant human bladder cancer cells. Mol. Cancer Ther. 6, 1022-1030 (2007).
26. Cheng AL, Hsu CH, Lin JK et al.: Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. AntiCancer Res. 21, 2895-2900 (2001).
27. Sharma R A, Euden SA, Platton S L et al.: Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin. Cancer Res. 10, 6847-6854 (2004).
28. Dhillon N, Aggarwal BB, Newman RA et al.: Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin. Cancer Res. 14, 4491-4499 (2008).
29. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB: Bioavailability of curcumin: problems and promises. Mol. Pharm. 4, 807-818 (2007).
30. Wang Y-J, Pan M-H, Cheng A-L et al.: Stability of curcumin in buffer solutions and characterization of its degradation products. J. Pharm. Biomed. Anal. 15, 1867-1876 (1997).
31. Liang G, Shao L, Wang Y et al.: Exploration and synthesis of curcumin analogues with improved structural stability both in vitro and in vivo as cytotoxic agents. Bioorg. Med. Chem. 17, 2623-2631 (2009).
32. Youssef D, Nichols CE, Cameron TS, Balzarini J, De Clercq E, Jha A: Design, synthesis, and cytostatic activity of novel cyclic curcumin analogues. Bioorg. Med. Chem. Lett. 17, 5624-5629 (2007).
33. Chen C, Johnston TD, Jeon H et al.: An in vitro study of liposomal curcumin: stability, toxicity and biological activity in human lymphocytes and Epstein-Barr virus-transformed human B-cells. Int. J. Pharm. 366, 133-139 (2009).
34. Shankeshi J, Aukunuru J: Preparation, characterization and evaluation of antidiabetic activity of a liposomal formulation encapsulating curcumin, an ayurvedic natural product. Pharmacist (Bhopal, India) 3, 1-5 (2008).
35. Marczylo TH, Verschoyle RD, Cooke DN, Morazzoni P, Steward W P, Gescher a J: Comparison of systemic availability of curcumin with that of curcumin formulated with phosphatidylcholine. Cancer Chemother. Pharmacol. 60, 171-177 (2007).
36. Bisht S, Feldmann G, Soni S et al.: Polymeric nanoparticle-encapsulated curcumin ("nanocurcumin"): a novel strategy for human cancer therapy. J. Nanobiotechnol. 5, 1-18 (2007).
37. Shi W, Dolai S, Rizk S et al.: Synthesis of monofunctional curcumin derivatives, clicked curcumin dimer, and a PAMAM dendrimer curcumin conjugate for therapeutic applications. Org Lett. 9, 5461-5464 (2007).
38. Safavy A, Raisch KP, Mantena S et al.: Design and development of water-soluble curcumin conjugates as potential anticancer agents. J. Med. Chem. 50, 6284-6288 (2007)
39. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K: Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release 65, 271-284 (2000).
40. Meister A, Anderson M: Glutathione. Ann. Rev. Biochem. 52, 711-760 (1983).
41. Huggins C, Moulton S: Esterases of testis and other tissues. J. Exp. Med. 88, 169-179 (1948).
42. Fu M, Wang C, Li Z, Sakamaki T, Pestell RG: Cyclin D1: normal and abnormal functions. Endocrinology 145, 5439-5447 (2004).
43. Hengstschlager M, Braun K, Soucek T, Miloloza A, Hengstschlager-Ottnad E: Cyclin-dependent kinases at the G1-S transition of the mammalian cell cycle. Mut. Res. 436, 1-9 (1999).
44. Ravindranath V, Chandrasekhara N: Absorption and tissue distribution of curcumin in rats. Toxicology 16, 259-265 (1980).
45. Pan M H, Huang T M, Lin JK: Biotransformation of curcumin through reduction and glucuronidation in mice. Drug Metab. Dispos. 27, 486-494 (1999).
46. Ireson C, Orr S, Jones DJL et at.: Characterization of metabolites of the chemopreventive agent curcumin in human and rat hepatocytes and in the rat in vivo, and evaluation of their ability to inhibit phorbol ester-induced prostaglandin E2 production. Cancer Res. 61, 1058-1064 (2001).
47. Yang KY, Lin LC, Tseng TY, Wang SC, Tsai TH: Oral bioavailability of curcumin in rat and the herbal analysis from Curcuma longa by LC-MS/MS. J. Chromatogr. BAnal. Technol. Biomed. Life Sci. 853, 183-189 (2007).
48. Lock R, Debnath J: Extracellular matrix regulation of autophagy. Curr. Opin. Cell Biol. 20, 583-588 (2008).
49. Aoki H, Takada Y, Kondo S, Sawaya R, Aggarwal BB, Kondo Y: Evidence that curcumin suppresses the growth of malignant gliomas in vitro and in vivo through induction of autophagy: role of Akt and extracellular signal-regulated kinase signaling pathways. Mol. Pharmacol. 72, 29-39 (2007).
50. Wong H, Bendayan R, Rauth A, Xue H, Babakhanian K, Wu X: A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymer-lipid hybrid nanoparticle system. J. Pharmacol. Exp. Thera. 317, 1372-1381 (2006)